Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML By Ogkologos - September 14, 2026 54 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PARADIGM study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR For AYAs with Advanced Cancer, Study Finds Serious Communication Gaps about... April 15, 2025 How Some Brain Tumors Hijack the Mind to Grow June 21, 2023 Haematologic Toxicity Not Increased with Immunochemotherapy Combinations Over Chemotherapy Treatment for... December 9, 2020 Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia June 22, 2018 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate A Poet’s Autobiography of Cancer Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival... FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for...
